The Cystic Fibrosis Foundation joined 72 chronic and rare disease organizations to send a letter to President-elect Trump and Congressional leadership.
Ginger Birnbaum and Mike Beatty lead efforts in Dallas for banner conference -- "teamMATEs for a Cure.”
At the 2016 North American Cystic Fibrosis Conference (NACFC) held on Oct. 27-29 in Orlando, Fla., the Cystic Fibrosis Foundation announced the recipients of seven awards given to members of the research and medical community whose achievements have helped advance cystic fibrosis research and care.
Garry Shandling leaves a legacy gift to the Foundation in honor of his late brother, who had cystic fibrosis.
The U.S. Food and Drug Administration (FDA) approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 6 to 11, who have two copies of the F508del mutation.
Piper Beatty, a two-time double-lung transplant recipient, testifies at an FDA meeting on organ transplantation.
On Thursday, September 22, experts from the Social Security Administration joined the CF community for a conversation on disability eligibility and the application process.
The lab will use the latest scientific advances -- including stem cell research and gene editing -- to accelerate new treatments for cystic fibrosis.
The CF Foundation applauds the Social Security Administration's updated eligibility requirements for disability benefits for people with respiratory diseases, including people with CF.
The Cystic Fibrosis Foundation invited more than 100 scientists to its research conference in Savannah, Ga., last month to discuss recent advancements in gene therapy, gene editing and stem-cell biology and how these new technologies could be applied to finding a one-time cure for cystic fibrosis.